The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
04 2019
Historique:
received: 21 02 2018
revised: 01 10 2018
accepted: 06 11 2018
pubmed: 29 12 2018
medline: 25 8 2020
entrez: 29 12 2018
Statut: ppublish

Résumé

Paediatric cancer survivors have a high risk of developing cardiac diseases, and the most frequent cardiac disease is heart failure (HF). The radiation dose-volume effects in the heart and cardiac substructures have not been explored in childhood cancer survivors (CCS). Therefore, the role of irradiated heart volume in the occurrence of HF among this population remains unclear. The aims of this study were to determine the doses and irradiated volumes of the heart and left ventricle (LV) related to the risk of HF in CCS and to investigate the impact of anthracycline exposure on this risk. A case-control study nested in the French Childhood Cancer Survivors Study cohort. The mean heart and left ventricular doses and volumes indicators were estimated by reconstruction of individual treatments. A total of 239 HF cases and 1042 matched controls were included. The median age of HF diagnosis was 25.1 years. The median volume of the heart that received ≥ 30 Gy was 61.1% for cases and 16.9% for controls. In patients who did not receive anthracycline, the risk of HF was increased 3.6-fold when less than 10% of the LV received ≥ 30 Gy when compared to patients who were not exposed to any cardiac radiation and anthracycline. Small irradiated volumes of the heart or LV were significantly associated with HF risk. To the author's knowledge, this is the first study to report a dose-response relationship based on dose-volume indicators in CCS, which can be translated efficiently into current clinical practice.

Sections du résumé

BACKGROUND
Paediatric cancer survivors have a high risk of developing cardiac diseases, and the most frequent cardiac disease is heart failure (HF). The radiation dose-volume effects in the heart and cardiac substructures have not been explored in childhood cancer survivors (CCS). Therefore, the role of irradiated heart volume in the occurrence of HF among this population remains unclear. The aims of this study were to determine the doses and irradiated volumes of the heart and left ventricle (LV) related to the risk of HF in CCS and to investigate the impact of anthracycline exposure on this risk.
METHODS AND RESULTS
A case-control study nested in the French Childhood Cancer Survivors Study cohort. The mean heart and left ventricular doses and volumes indicators were estimated by reconstruction of individual treatments. A total of 239 HF cases and 1042 matched controls were included. The median age of HF diagnosis was 25.1 years. The median volume of the heart that received ≥ 30 Gy was 61.1% for cases and 16.9% for controls. In patients who did not receive anthracycline, the risk of HF was increased 3.6-fold when less than 10% of the LV received ≥ 30 Gy when compared to patients who were not exposed to any cardiac radiation and anthracycline.
CONCLUSIONS
Small irradiated volumes of the heart or LV were significantly associated with HF risk. To the author's knowledge, this is the first study to report a dose-response relationship based on dose-volume indicators in CCS, which can be translated efficiently into current clinical practice.

Identifiants

pubmed: 30592114
doi: 10.1002/ejhf.1376
doi:

Substances chimiques

Anthracyclines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

509-518

Subventions

Organisme : Electricité de France (EDF)
Pays : International
Organisme : Pfizer Foundation for childhood and adolescent health
Pays : International
Organisme : Ligue Nationale Contre le Cancer (LNCC)
Pays : International
Organisme : Institut de Recherche en Santé Publique (IRESP)
Pays : International
Organisme : Programme Hospitalier de Recherche Clinique (PHRC)
Pays : International
Organisme : Agence Française de Sécurité Sanitaire et Produit de Santé (AFSSAPS)
Pays : International
Organisme : French Agence Nationale Pour la Recherche Scientifique (Hope-Epi Project)
Pays : International

Informations de copyright

© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.

Auteurs

Imène Mansouri (I)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Rodrigue S Allodji (RS)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Catherine Hill (C)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Chiraz El-Fayech (C)

CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.
Department of Childhood and Adolescent Oncology, Gustave Roussy, Villejuif, France.

François Pein (F)

Institut de Cancérologie de l'Ouest ICO Centre René Gauducheau, Saint-Herblain (Nantes), France.

Stéphanie Diallo (S)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.
Centre Hospitalier de Gonesse, Gonesse, France.

Boris Schwartz (B)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Giao Vu-Bezin (G)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Cristina Veres (C)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.
Institut Curie, Paris, France.

Vincent Souchard (V)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Agnès Dumas (A)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Stéphanie Bolle (S)

Departement of Radiotherapy, Gustave Roussy, Villejuif, France.

Cécile Thomas-Teinturier (C)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.
Department of Pediatric Endocrinology, AP-HP Hôpitaux Paris-Sud, Le Kremlin Bicêtre, France.

Hélène Pacquement (H)

Institut Curie, Paris, France.

Martine Munzer (M)

Institut Jean Godinot, Reims, France.

Pierre-Yves Bondiau (PY)

Centre Antoine Lacassagne, Nice, France.

Delphine Berchery (D)

Centre Claudius Régaud, Toulouse, France.

Brice Fresneau (B)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.
Department of Childhood and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Odile Oberlin (O)

Department of Childhood and Adolescent Oncology, Gustave Roussy, Villejuif, France.

Ibrahima Diallo (I)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Florent De Vathaire (F)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Nadia Haddy (N)

CESP, Université Paris-Saclay, Villejuif, France.
CESP, INSERM U 1018, Cancer and Radiation team, Gustave Roussy, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH